La chaîne d'options affiche les données clés des options sur actions de Sidus Space à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Sidus Space..

Sidus Space (NASDAQ:SIDU) Stock, Chaîne d'Options

Sidus Space

Sidus Space Inc is a Space and Defense as-a-Service company focused on providing complex space hardware, satellite/spacecraft design, manufacture, launch, and data solutions for both government and commercial in-space missions for all destinations through the solar system. This includes a Space-based infrastructure of multi-mission satellites with hyperspectral, multi-spectral, and other sensors to provide monitoring services and solutions to multiple sectors and industries. The company supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers.

Sidus Space Inc

SIDUS HEROES

CV Sciences, Inc. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTCQB">CVSI</a>), a <a href="http://benzinga.com/topic/hemp">hemp</a>-focused wellness company, announced stable revenue in its Q3 2024 financials on Thursday. The company generated $3.9 million in revenue, a slight decline from $4.1 million in Q3 2023, yet maintained a gross margin of 46%, up from 45.1% the previous year.
<h4 class="wp-block-heading">Q3 2024 Financial Highlights</h4>
<ul>
<li>Revenue: $3.9 million, a 5% decline from $4.1 million in Q3 2023 and stable compared to <a href="https://www.benzinga.com/markets/cannabis/24/08/40344002/hemp-focused-cv-sciences-reports-flat-revenue-and-over-8-yoy-increase-in-gross-profit-in-q2">$4 million in Q2 2024</a>.</li>
<li>Net loss: $456,000, slightly higher than the $447,000 loss in Q3 2023.</li>
<li>Adjusted EBITDA: Loss of $75,000, significantly improved from a loss of $361,000 in Q3 2023.</li>
<li>Gross profit: $1.78 million, a slight decrease from $1.84 million in Q3 2023, reflecting an improved gross margin of 46%, up from 45.1% in the same period last year.</li>
</ul>
<h3 class="wp-block-heading">New Product Lines Boost Growth</h3>
Operating with a cash balance of $1 million, CV Sciences recorded an adjusted EBITDA loss of $75,000, <a href="https://www.benzinga.com/markets/cannabis/24/03/37988133/hemp-focused-wellness-co-moves-closer-to-profitability-reports-flat-2023-revenue-increase-in-gro">inching closer</a> to cash flow break-even.
Furthermore, the company's recent launches, including the cannabinoid-free +PlusHLTH supplement line, target cognitive health, stress relief and metabolism support. Additionally, CV Sciences expanded its pet health segment with hip, joint and calming chews, aiming to capture a broader consumer base.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Management Commentary</h3>
CEO Joseph Dowling highlighted the <a href="https://www.benzinga.com/markets/cannabis/24/08/40344002/hemp-focused-cv-sciences-reports-flat-revenue-and-over-8-yoy-increase-in-gross-profit-in-q2">steady core revenue</a> in a challenging environment, noting new products and acquisitions as positioning factors for growth in 2025. &#8220;Our third quarter 2024 progress demonstrates our continuous commitment to innovation and cost-efficient execution as we move closer to profitability and positive cash flow,&#8221; Dowling <a href="https://www.prnewswire.com/news-releases/cv-sciences-inc-reports-third-quarter-2024-financial-results-302305079.html">said</a> in a press release.
Read Also: <a href="https://www.benzinga.com/24/11/41971875/cbd-pioneer-charlottes-web-narrows-loss-in-q3-focuses-on-long-term-growth-amid-challenging-cannabis-industry-environment">CBD Pioneer Charlotte&#8217;s Web Narrows Loss In Q3, Focuses On Long-Term Growth</a>
"We look forward to organically grow our business and pursue additional M&amp;A opportunities in the near future to improve our top-line revenue, profitability and shareholder value," he added.
<h3 class="wp-block-heading">CV Sciences Holds Top Market Spot</h3>
In Q3, CV Sciences further solidified its market position, maintaining top-seller status in the natural products retail channel, according to SPINS data. The company also secured $0.9 million in financing from Streeterville, aimed at fueling operational and product expansion.
CVSI Price Action CVSI's shares were trading 7.73% lower at $0.04235 per share at the time of this writing around 12:35 PM ET Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41974843/cbd-pharma-co-medipharm-37-increase-in-q3-international-sales-15-yoy-revenue-growth">CBD Pharma Co. MediPharm: 37% Increase In Q3 International Sales, 15% YoY Revenue Growth</a></li>
</ul>

Cannabis

Earnings

CVSI

CV Sciences Q3: Revenue Stable Amid New Launches, Financing

News

Trading Ideas

RIVN

iShares Trust Barclays 20+ Year Treasury Bond Fund

Soros Fund Management 13F Shows Exited Position In SPDR S&P 500 ETF, Previously Holding 450,000 Shares; Exited Stake In Rivian Automotive Call Options, Previously Holding 5,450,000 Shares; Exited Put Position In Ishares 20+ Year Treasury Bond ETF, Previously Holding 360,000 Shares; Exited Stake In Westrock Co, Previously Holding 3,342,953 Shares;  Exited Stake In Livongo Health Convertible Notes, Previously Holding $45M In Principal

PMNT

Perfect Moment Q2 EPS $(0.17) Up From $(0.29) YoY; Revenue $3.833M Down From $5.888M YoY

Canaccord Genuity analyst Joseph Vafi maintains Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Buy and raises the price target from $22 to $32.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Buy on Hut 8, Raises Price Target to $32

<a href="https://truthsocial.com/@realDonaldTrump/113483513301208163" title="https://truthsocial.com/@realDonaldTrump/113483513301208163">https://truthsocial.com/@realDonaldTrump/113483513301208163</a>

Macro Notification

Politics

General

Trump Picks Jay Clayton For Chairman Of U.S. Securities And Exchange Commission

PXLW

Pixelworks Enters $10M "At-The-Market" Equity Offering Agreement With Roth Capital, Allowing Periodic Common Stock Sales With 2.5% Commission; Roth To Act As Sales Agent

GOOGL

LBRDA

Soros Fund Management 13F Shows Decreased Stake In Rivian Automotive Convertible Notes By 21% To $155.9M In Principal; Decreased Stake In Wayfair Convertible Notes By 11% To $119.5M In Principal; Decreased Stake In Liberty Broadband Corp By 19% To 1,119,893 Shares; Decreased Stake In Alphabet Class A By 43% To 517,890 Shares; Decreased Put Position In Ishares IBoxx High Yield Corporate Bond ETF By 40% To 1,500,000 Shares

Discover Financial Reports $100.7B In Credit Card Loans As Of October 2024, Up From $98.7B YoY; Average Balances Remain Stable At $100.2B; Net Principal Charge-Off Rate Drops To 4.31% With Disaster Relief Impact, Though Up From 4.42% YoY; Delinquency Rate Rises Slightly To 3.87%

Management

Zillow Group Appoints Jun Choo As COO

Offerings

GYRE

Gyre Therapeutics Files For Up To $150M Mixed Shelf

WIIM

IZEA

IZEA Worldwide shares are trading lower after the company reported worse-than-expected Q3 financial results.

BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.58) by 32.76 percent.

Earnings Beats

BKYI

BIO-key Intl Q3 2024 Adj EPS $(0.39) Beats $(0.58) Estimate

TFFP

TFF Pharmaceutical shares are trading lower after the company announced it will wind down its operations.

Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.52) by 53.85 percent.

ENVB

Enveric Biosciences Q3 2024 GAAP EPS $(0.24) Beats $(0.52) Estimate

AKYA

Akoya Biosciences shares are trading lower after the company reported worse-than-expected Q3 financial results.

DOCN

OKTA

Soros Fund Management 13F Shows Increased Put Position In SPDR S&P 500 ETF By 608% To 2,123,000 Shares; Increased Stake In Ishares Financial Select Sector SPDR ETF By 22,720% To 2,800,000 Shares; Increased Stake In JD.com By 114% To 2,730,000 Shares; Increased Stake In Okta Convertible Notes By 75% To $79.1M In Principal; Increased Stake In DigitalOcean Convertible Notes By 302% To $116.5M In Principal

Buybacks

Primerica Board Authorizes $450M Share Repurchase Program To Occur Through December 31, 2025

XPON

Expion360 shares are trading lower after the company reported a year-over-year decline in Q3 revenue results.

Asset Sales

BLFS

BioLife Solutions Sells Subsidiary, Arctic Solutions, For $6.1M

BENF

Beneficient Q2 2025 Revenue $8.6M Vs $(42.8M) YoY

Sidus Space, Inc. (SIDU) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Sidus Space (NASDAQ:<a href="https://investorplace.com/stock-quotes/sidu-stock-quote/">SIDU</a>) just reported results for the second quarter of 2024.<ul><li>Sidus Space reported earnings per share of -99 cents.</li><li>The company reported revenue of $927,570.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/sidu-stock-earnings-sidus-space-for-q2-of-2024/">SIDU Stock Earnings: Sidus Space Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SIDU Stock Earnings: Sidus Space Reported Results for Q2 2024

Sidus Space awarded $2 million contract for U.S. Navy propulsion program

Sidus Space receives additional contract for NASA ASTRA

Small private steps are a giant leap for commercial space

Sidus Space signs agreement with Neuraspace

Sidus Space (SIDU) announced the successful completion of the critical design review for LizzieSat NL, a laser communication satellite contracted b...

Sidus clears design review for Netherlands laser comm satellite

Sidus Space (SIDU) announced a strategic communication upgrade for its LizzieSat platform, integrating Iridium-enabled technology into future satel...

Sidus Space announces communication upgrade for LizzieSat platform

Sidus Space slides 18%, prices $7M offering

Sidus Space GAAP EPS of -$0.93, revenue of $1.86M

ARKX

ASTS

BKSY

FOUR

KULR

LLAP

LUNR

MDALF

MNTS

RKLB

SATS

SIDU

SPCE

SPIR

TSAT

Press Releases

Sidus Space Announces LizzieSat™-2 is Ready for Launch

Sidus Space Receives FCC Approval for Remote Sensing Satellite Micro Constellation License, Expanding Footprint in Low Earth Orbit

Sidus Space Clears Critical Design Review for Netherlands Laser Comm Satellite

Sidus Space to Present at the 2024 ThinkEquity Conference

Sidus Space Announces Iridium-Powered Communication Upgrade for LizzieSat™ Platform

Sidus Space to Host Third Quarter 2024 Financial Results Conference Call on November 14th at 5:00 p.m. ET

Sidus Space Selected to Exclusively Build Lonestar Data Holdings Lunar Data Storage Spacecraft Fleet

Sidus Space Announces Pricing of Public Offering

Sidus Space Announces Closing of $7.0 Million Public Offering

Sidus Space Reports Third Quarter 2024 Financial Results and Provides Business Update

Comments

Sidus Space

Sidus Space (SIDU) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL